First human trial tests promising drug for devastating rare cancer
NCT ID NCT03485547
Summary
This early-stage study tested the safety and initial effectiveness of the drug venetoclax for adults with a rare and aggressive blood cancer called BPDCN. The trial involved a small group of patients to find the safest dose and see if the drug could help control the disease. It was based on lab tests showing the drug could kill BPDCN cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.